---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-146576"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:30:53.218402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IN8bio preclinical data shows DeltEx gamma-delta T cells kill ovarian cancer cells, including resistant lines

## Summary
- Data presented at ASGCT 2023 demonstrate DeltEx T cells target and kill ovarian cancer cells even in platinum-resistant lines.
- Temozolomide (TMZ) combined with PARP inhibitors synergistically increased NKG2D-L expression, enhancing tumor cell visibility to gamma-delta T cells.
- CEO William Ho highlighted synergy of gamma-delta T cells with chemotherapy for solid tumors beyond the brain.
- CSO Lawrence Lamb noted potential for INB-400 in ovarian cancer and other solid tumors; further evaluation planned.
- Preclinical proof-of-concept supports DeltEx Drug Resistance Immunotherapy (DeltEx DRI) platform in challenging indications.

## SEC filing metadata
- accession: 0001193125-23-146576
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523146576/0001193125-23-146576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523146576/d477840d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-146576
- JSON: https://secwatch.observer/filing/0001193125-23-146576.json
- Plain text: https://secwatch.observer/filing/0001193125-23-146576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.